Sort
39,280 grants matching “leukemia”
Reduced Traumatic Lumbar Puncture Rates in Pediatric Oncology Patients Through Development of an AI-Assisted, Ultrasound-Based Interventional Guidance Platform
$1,073,736Frank William Mauldin · Rivanna Medical, Inc. · R44 · FY2025 · CA
Studies of Populations Exposed to Diagnostic Medical Radiation
$1,073,674Amy Berrington De Gonzalez · Division Of Cancer Epidemiology And Genetics · ZIA · FY2017 · CA
Integrated, Sensitive Metabolomics Platform (RMI)
$1,072,854Harvard University (Medical School) · R21 · FY2004 · DK
FANCONI ANEMIA:GENOTYPE-PHENOTYPE CORRELATIONS
$1,072,270Settara Chandrasekharappa · National Human Genome Research Institute · ZIA · FY2024 · HG
Sphingolipids in Cancer Therapy and Angiogenesis
$1,071,665Yusuf Awni Hannun · Medical University Of South Carolina · P01 · FY2007 · CA
Translating genomic discoveries to improved outcomes for high risk acute leukemia
$1,071,276Charles G. Mullighan · St. Jude Children'S Research Hospital · R35 · FY2017 · CA
Using the Preimplantation Factor (PIF) to Treat Graft-versus-Host Disease
$1,071,030Pramod Terse · National Center For Advancing Translational Sciences · ZIA · FY2021 · TR
The 10,000 Families Cohort: a new study to understand the environmental causes of cancer
$1,070,671Jenny N. Poynter · University Of Minnesota · UG3 · FY2021 · CA
AC-225 Imaging R01 Transfer
$1,070,638Javier Caravaca · University Of Calif-Lawrenc Berkeley Lab · R01 · FY2025 · EB
Radioimmunotherapy Based Transplant Regimens for Treatment of B-Cell Lymphoma and
$1,070,477Stephen J Forma · Beckman Research Institute/City Of Hope · P01 · FY2009 · CA
Non-clinical Combination Pharmacology Studies and Phase 1 Clinical Development of IO-202 in Acute Myeloid Leukemia (AML)
$1,070,000Charlene Liao · Immune-Onc Therapeutics, Inc. · R44 · FY2021 · CA
Non-clinical Combination Pharmacology Studies and Phase 1 Clinical Development of IO-202 in Acute Myeloid Leukemia (AML)
$1,070,000Charlene Liao · Immune-Onc Therapeutics, Inc. · R44 · FY2020 · CA
How the 3D Architecture of the Brain Shapes Cancer Cell Fate Decisions
$1,068,000Mariella Gruber Filbin · Dana-Farber Cancer Inst · DP2 · FY2024 · NS
Transplant Models
$1,067,628Ronald Gress · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Repository Services for epidemiology studies
$1,066,827Larry Arthur · Science Applications International Corp · N01 · FY2009 · CA
Molecular-Cellular Regulation of Hematopoietic Stem Cells
$1,066,384Jonathan R Keller · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Targeting Pediatric Cancer Vulnerabilities
$1,066,178Kimberly Stegmaier · Dana-Farber Cancer Inst · R35 · FY2023 · CA
Establishing and Interpreting Abnormal DNA Methylation in Cancer
$1,065,709Peter A Jones · Van Andel Research Institute · R35 · FY2024 · CA
Targeting Pediatric Cancer Vulnerabilities
$1,065,492Kimberly Stegmaier · Dana-Farber Cancer Inst · R35 · FY2025 · CA
Development of Recombinant Toxins to Treat Hematologic Malignancies
$1,065,252Robert Kreitman · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
MOLECULAR BIOLOGY OF HEMOPOIETIC STEM CELLS
$1,064,959University Of Washington · P01 · FY2000 · DK
CHILDHOOD LEUKEMIA AND ENVIRONMENTAL EXPOSURES
$1,064,504University Of California Berkeley · R01 · FY2000 · ES
CH in Aging and Exceptional Longevity
$1,064,072Aditi Shastri · Albert Einstein College Of Medicine · R01 · FY2025 · AG
Development of JS-K as an anti-leukemic agent
$1,063,969Paul J Shami · University Of Utah · R01 · FY2009 · CA
Targeting Agents for Human and Canine Lymphoma
$1,063,877Kit S Lam · University Of California At Davis · U19 · FY2006 · CA